ID: ALA2165267
PubChem CID: 71455134
Max Phase: Preclinical
Molecular Formula: C32H58N12O9
Molecular Weight: 754.89
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O
Standard InChI: InChI=1S/C32H58N12O9/c1-17(2)15-21(28(49)41-20(31(52)53)8-5-13-39-32(37)38)42-27(48)19(10-11-24(35)45)40-29(50)23-9-6-14-44(23)30(51)22(16-25(36)46)43-26(47)18(34)7-3-4-12-33/h17-23H,3-16,33-34H2,1-2H3,(H2,35,45)(H2,36,46)(H,40,50)(H,41,49)(H,42,48)(H,43,47)(H,52,53)(H4,37,38,39)/t18-,19-,20-,21-,22-,23-/m0/s1
Standard InChI Key: WOPXTMYICCIEQV-LLINQDLYSA-N
Molfile:
RDKit 2D
53 53 0 0 0 0 0 0 0 0999 V2000
17.7923 -1.7938 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
17.7320 -2.6166 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
18.3456 -3.8996 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
18.4101 -3.0851 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9896 -2.9712 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.9294 -3.7941 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.1828 -4.1486 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
16.1225 -4.9715 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
15.3843 -5.3302 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.1525 -2.7221 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
19.8304 -3.1822 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2467 -3.2919 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
20.5687 -2.8277 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.7701 -4.0051 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.4440 -4.4651 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3837 -5.2880 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
21.1947 -4.1148 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
20.6373 -2.0090 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
21.2871 -1.5349 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.0186 -2.7282 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
22.0186 -1.9032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
21.2863 -0.7023 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
19.9970 -1.3738 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
20.3898 -0.5704 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7264 -1.4948 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
23.4425 -1.9032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7264 -3.1407 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
23.4425 -2.7282 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.1587 -1.4948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.8625 -1.9032 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5828 -1.4948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5828 -0.6698 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
26.2864 -1.9032 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.1587 -3.1407 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.1587 -3.9615 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
25.5828 -3.9615 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
24.8625 -4.3740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.4425 -4.3740 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
23.4425 -5.1948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
22.7264 -5.6073 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.1587 -5.6073 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
28.4267 -5.6073 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.1387 -5.1948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
29.8506 -5.6073 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
29.1387 -4.3740 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
24.8625 -5.1948 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
25.5828 -5.6073 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
24.8625 -6.8448 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
25.5828 -6.4323 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2864 -5.1948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.0026 -5.6073 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
27.7146 -5.1948 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
26.2864 -6.8448 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4 10 1 0
13 18 1 0
21 25 1 0
28 34 1 0
37 46 1 0
49 53 1 0
2 1 1 6
2 4 1 0
4 3 2 0
2 5 1 0
5 6 1 0
6 7 1 0
7 8 1 0
8 9 1 0
10 11 1 0
11 13 1 0
13 12 2 0
11 14 1 6
14 15 1 0
15 16 2 0
15 17 1 0
18 19 1 0
19 21 1 1
21 20 2 0
19 22 1 0
23 24 1 0
24 22 1 0
23 18 1 0
26 25 1 1
26 28 1 0
28 27 2 0
26 29 1 0
29 30 1 0
30 31 1 0
31 32 2 0
31 33 1 0
35 34 1 6
35 37 1 0
37 36 2 0
35 38 1 0
38 39 1 0
39 40 1 0
39 41 1 0
42 43 1 0
43 44 1 0
43 45 2 0
47 46 1 1
47 49 1 0
49 48 2 0
47 50 1 0
50 51 1 0
51 52 1 0
52 42 1 0
M END| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 754.89 | Molecular Weight (Monoisotopic): 754.4450 | AlogP: -4.09 | #Rotatable Bonds: 25 |
| Polar Surface Area: 374.13 | Molecular Species: ZWITTERION | HBA: 11 | HBD: 12 |
| #RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 17 | #RO5 Violations (Lipinski): 3 |
| CX Acidic pKa: 4.07 | CX Basic pKa: 13.57 | CX LogP: -7.17 | CX LogD: -10.44 |
| Aromatic Rings: ┄ | Heavy Atoms: 53 | QED Weighted: 0.02 | Np Likeness Score: 0.22 |
| 1. Abramson HN.. (2011) The lipogenesis pathway as a cancer target., 54 (16): [PMID:21726077] [10.1021/jm2005805] |
| 2. and Abramson, Hanley N HN. 2011-08-25 The lipogenesis pathway as a cancer target. [PMID:21726077] |
| 3. and Abdel-Magid, Ahmed F AF. 2015-08-13 Fatty Acid Synthase (FASN) Inhibitors as Potential Treatment for Cancer, Obesity, and Liver Related Disorders. [PMID:26288680] |
| 4. Mullen, Genevieve E GE and Yet, Larry L. 2015-10-15 Progress in the development of fatty acid synthase inhibitors as anticancer targets. [PMID:26364942] |
| 5. Zhu, Mingzhao and 19 more authors. 2017-06-01 A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids. [PMID:28236510] |
Source(1):